RegeneRx Licensee Acquired by Korean Biopharmaceutical Group

Rhea-AI Summary

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced the acquisition of its licensee, GtreeBNT, by HLB Group, a Korean biopharmaceutical firm, for approximately US$80 million in new stock and convertible bonds. This capital infusion aims to expedite ongoing clinical trials and new drug approvals, with a focus on RGN-259. The new management is expected to be appointed on October 29, 2021, and further updates will be shared at RegeneRx's Annual Stockholder Meeting on November 10, 2021.

Positive

• Acquisition provides GtreeBNT with US$80 million for clinical programs.
• Expected acceleration of clinical trials for RGN-259 and RGN-137.

Negative

• None.

ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S. 

GtreeBNT announced that as part of its acquisition the company would issue approximately US$80 million of new stock and convertible bonds to HLB Group to fund ongoing programs. The new capital should speed up the clinical trials currently in progress and allow the company to focus on new drug approval. RGN-259 will remain a priority for the company. 

HLB's recommended executives are expected to be appointed at the general meeting scheduled for October 29, 2021. Won Yang, the current CEO of GtreeBNT, is expected to remain as the chief research officer and continue to lead the development of new drugs after the acquisition. 

RegeneRx has scheduled its 2021 Annual Stockholder Meeting for November 10, 2021 and hopes to have additional details on the acquisition and its effect on GtreeBNT's clinical development activities and timing related to RGN-259 and RGN-137, products developed for the treatment of dry eye syndrome, neurotrophic keratitis, and epidermolysis bullosa.

"The fact that GtreeBNT will receive a significant capital infusion related to the transaction, we believe, should benefit the development of the products we licensed to the company.  As soon as practicable after we receive any new information from the new management related to our products we will update our stockholders," stated J.J. Finkelstein, president and chief executive.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac/neuro and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  Forward-looking statements in this press release include, but are not limited to statements from us, or our U.S. joint venture partner, GtreeBNT,  or from independent news reports. Please view risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2020, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

 

View original content:https://www.prnewswire.com/news-releases/regenerx-licensee-acquired-by-korean-biopharmaceutical-group-301385531.html

SOURCE RegeneRx Biopharmaceuticals, Inc.

FAQ

What is the significance of GtreeBNT's acquisition by HLB Group?

The acquisition provides GtreeBNT with US$80 million for clinical trials, potentially enhancing the development of licensed products, including RGN-259.

When will the new management for GtreeBNT be appointed?

The new management is expected to be appointed at a general meeting on October 29, 2021.

What updates can we expect regarding RegeneRx's products after the acquisition?

RegeneRx plans to provide updates on its products at the Annual Stockholder Meeting on November 10, 2021.